Basket | Login | Register

 
 
 
 

PharmaCog

Related News


Pharmacog Logo

PharmaCog is short for “Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development”. It is a partnership of 32 academic and industry actors from 7 countries, co-ordinated by GlaxoSmithKline R&D and the Université de la Méditerranée, started its activities on January 1, 2010 thanks to significant funding (EUR 20.2 million) from the Innovative Medicines Initiative. Its launch marks the start of the most ambitious European project for tackling bottlenecks in Alzheimer's disease research and drug discovery.

PharmaCog will provide the tools needed to define more precisely the potential of a drug candidate, reduce the development time of new medicines and thus accelerate the approvals of promising new medicines.

 

Downloads

 

 

Last Updated: Wednesday 21 May 2014

 

 
  • Acknowledgements

    The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No 115009.
  • Innovative Medicines Initiative
  • European Union
  • European Federation of Pharmaceutical Industries and Associations
 
 

Options

  • Send this page to a friend